Impellam Group PLC provided earnings guidance for the full year ending December 29, 2017. Notwithstanding the ongoing disruption in the UK healthcare market and generally challenging trading conditions in the UK including Brexit uncertainty, pay rate stagnation and increased cost of compliance, whilst EBITDA is likely to be slightly below market expectations the Board confirmed that it expects to deliver 2017 pre-tax profits in line with market expectations. Cash generation continues to be strong and it expects net debt to be lower (circa £89 million) than at the end of 2016 (31 December 2016: £95.2 million). Whilst the UK markets have been challenging, the Board remains confident that the Groups strategic initiatives, combined with both selective investment in growth opportunities and prudent cost management will deliver sustainable profit streams into 2018.